Hypothermia for moderate or severe neonatal encephalopathy in low-income and middle-income countries (HELIX): a randomised controlled trial in India, Sri Lanka, and Bangladesh
Sudhin Thayyil, Stuti Pant, Paolo Montaldo, Deepika Shukla, Vânia Oliveira, Phoebe Ivain, Paul Bassett, Ravi Swamy, Josephine Mendoza, Maria Moreno-Morales, Peter Lally, Naveen Benakappa, Prathik Bandiya, Indramma Shivarudhrappa, Jagadish Somanna, Usha B Kantharajanna, Ankur Rajvanshi, Sowmya Krishnappa, Poovathumkal K. Joby, Kumutha Jayaraman, Rema Chandramohan, Chinnathambi Kamalarathnam, Monica Sebastian, Indumathi A Tamilselvam, Usha D Rajendran, Radhakrishnan Soundrarajan, Vignesh Kumar, Harish Sudarsanan, Padmesh Vadakepat, Kavitha Gopalan, Mangalabharathi Sundaram, Arasar Seeralar, Vinayagam Prakash, Mohamed Sajjid, Mythili Baburaj, Kanchana D. Murugan, Babu Peter Sathyanathan, Elumalai S. Kumaran, Jayashree Mondkar, Swati Manerkar, Anagha Joshi, Kapil Dewang, Swapnil Bhisikar, Pavan Kalamdani, Vrushali Bichkar, Saikat Patra, Kapil Jiwnani, Mohammod Shahidullah, Sadeka Choudhury Moni, Ismat Jahan, Mohammad Abdul Mannan, Sanjoy Kumer Dey, Mst. N. Nahar, Mohammad Naimul Islam, Kamrul Hassan Shabuj, Ranmali Rodrigo, Samanmali Sumanasena, Thilini Abayabandara‐Herath, Gayani K Chathurangika, Jithangi Wanigasinghe, Radhika Sujatha, Sobhakumar Saraswathy, Aswathy Rahul, Saritha J Radha, Manoj K. Sarojam, Vaisakh Krishnan, Mohandas Nair, Sahana Devadas, Savitha Chandriah, Harini Venkateswaran, Constance Burgod, Manigandan Chandrasekaran, Gaurav Atreja, Pallavi Muraleedharan, Jethro Herberg, W.K. Chong, Neil J. Sebire, Ronit Pressler, Siddarth Ramji, Seetha Shankaran, Sudhin Thayyil, Stuti Pant, Paolo Montaldo, Deepika Shukla, Vânia Oliveira, Phoebe Ivain, Paul Bassett, Ravi Swamy, Josephine Mendoza, Maria Moreno-Morales, Peter Lally, Naveen Benakappa, Prathik Bandiya, Indramma Shivarudhrappa, Jagadish Somanna, Usha B. Kantharajanna, Ankur Rajvanshi, Sowmya Krishnappa, Poovathumkal K. Joby, Kumutha Jayaraman
Abstract
BACKGROUND: Although therapeutic hypothermia reduces death or disability after neonatal encephalopathy in high-income countries, its safety and efficacy in low-income and middle-income countries is unclear. We aimed to examine whether therapeutic hypothermia alongside optimal supportive intensive care reduces death or moderate or severe disability after neonatal encephalopathy in south Asia. METHODS: We did a multicountry open-label, randomised controlled trial in seven tertiary neonatal intensive care units in India, Sri Lanka, and Bangladesh. We enrolled infants born at or after 36 weeks of gestation with moderate or severe neonatal encephalopathy and a need for continued resuscitation at 5 min of age or an Apgar score of less than 6 at 5 min of age (for babies born in a hospital), or both, or an absence of crying by 5 min of age (for babies born at home). Using a web-based randomisation system, we allocated infants into a group receiving whole body hypothermia (33·5°C) for 72 h using a servo-controlled cooling device, or to usual care (control group), within 6 h of birth. All recruiting sites had facilities for invasive ventilation, cardiovascular support, and access to 3 Tesla MRI scanners and spectroscopy. Masking of the intervention was not possible, but those involved in the magnetic resonance biomarker analysis and neurodevelopmental outcome assessments were masked to the allocation. The primary outcome was a combined endpoint of death or moderate or severe disability at 18-22 months, assessed by the Bayley Scales of Infant and Toddler Development (third edition) and a detailed neurological examination. Analysis was by intention to treat. This trial is registered with ClinicalTrials.gov, NCT02387385. FINDINGS: We screened 2296 infants between Aug 15, 2015, and Feb 15, 2019, of whom 576 infants were eligible for inclusion. After exclusions, we recruited 408 eligible infants and we assigned 202 to the hypothermia group and 206 to the control group. Primary outcome data were available for 195 (97%) of the 202 infants in the hypothermia group and 199 (97%) of the 206 control group infants. 98 (50%) infants in the hypothermia group and 94 (47%) infants in the control group died or had a moderate or severe disability (risk ratio 1·06; 95% CI 0·87-1·30; p=0·55). 84 infants (42%) in the hypothermia group and 63 (31%; p=0·022) infants in the control group died, of whom 72 (36%) and 49 (24%; p=0·0087) died during neonatal hospitalisation. Five serious adverse events were reported: three in the hypothermia group (one hospital readmission relating to pneumonia, one septic arthritis, and one suspected venous thrombosis), and two in the control group (one related to desaturations during MRI and other because of endotracheal tube displacement during transport for MRI). No adverse events were considered causally related to the study intervention. INTERPRETATION: Therapeutic hypothermia did not reduce the combined outcome of death or disability at 18 months after neonatal encephalopathy in low-income and middle-income countries, but significantly increased death alone. Therapeutic hypothermia should not be offered as treatment for neonatal encephalopathy in low-income and middle-income countries, even when tertiary neonatal intensive care facilities are available. FUNDING: National Institute for Health Research, Garfield Weston Foundation, and Bill & Melinda Gates Foundation. TRANSLATIONS: For the Hindi, Malayalam, Telugu, Kannada, Singhalese, Tamil, Marathi and Bangla translations of the abstract see Supplementary Materials section.